Law firm Corrs Chambers Westgarth is following in the footsteps of Squire Patton Boggs, with both now challenging a ruling that halted their shareholder class actions against logistics startup GetSwift.
Luxury home builder Glenville has won an appeal of a ruling that shielded certain documents from production by legal professional privilege in a lawsuit against global packaging giant Amcor over liability for asbestos remediation at a former Amcor paper mill site in a Melbourne suburb.
In a major loss for the ACCC, the Full Federal Court on Friday tossed the competition regulator’s challenge to a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
A judge overseeing a trial against S&P Global over its ratings of synthetic collateralised debt obligations has tossed the company’s damages expert, saying she lacked sufficient expertise to provide an opinion on the value of the instruments.
The Transport Workers Union has lost its bid for a stay of a court order that it pay a $270,000 penalty for allegedly keeping almost 21,000 lapsed members on its register and failing to keep copies of records.
Blockbuster has struck out in its challenge to a ruling that it could not recover a cent from a husband and wife franchisee after the pair sold the store’s assets without consent and admitted to breaching the franchise agreement.
The Australian Securities and Investments Commission has won leave to appeal to the High Court a ruling that threw out its case against former directors of collapsed retirement village owner Prime Trust.
The Full Federal Court on Tuesday dismissed an appeal by aviation services company Aerocare of a ruling rejecting an enterprise agreement the Transport Workers Union called “substandard”.
Telecom giant Optus has come up short in a Federal Court challenge to trademark registration for health services company Optum, with a judge saying the two company’s marks — despite the difference of just one letter — were distinct enough.
A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.